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  This dissertation examined the impact of Medicare Plan D on medication 
compliance in Medicare beneficiaries at University of Texas Health Center at Tyler, TX. 
Data were collected before and after the implementation of Plan D. The impacts of 
various types of benefits, such as private insurance, employer insurance and pharmacy 
assistance programs were evaluated in terms of impact on drug compliance. Medication 
compliance was found to increase in those respondents without Plan D. Plan D was 
found to be a predictor of those who spent less on basics in order to buy medications. 
Although compliance increased in general, these increases could not be attributed to 
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 Since it was signed into law in 1965 as a part of President Lyndon Johnson’s 
Great Society, Medicare has provided a basic program of health insurance for those 
Americans age 65 and older. Later, in 1972, this insurance program also included 
coverage for those Americans under age 65 with end stage renal disease and those 
who were disabled. 
 Although Medicare covers part of the costs of medical care for physicians, 
hospitals, some skilled nursing services and home health through its Parts A and B, the 
basic benefits of Medicare have not previously covered most outpatient prescription 
medications. Of course, the increasing numbers of Americans with chronic illness 
requiring multiple medications and the increasing expense associated with prescription 
medications has empowered the federal government to address the need for medication 
coverage as a part of Medicare. 
 A recent national survey of senior Medicare beneficiaries extensively examined 
use of prescription medication, prescription medication insurance coverage, and 
reasons for medication non-adherence (Safran, Neuman, Schoen, Kitchman, Wilson, 
Cooper et al., 2005). Overall, non-adherence due to medication cost was 26.3%. The 
University of Texas Health Center Internal Medicine Clinic aggressively enrolled 
Medicare patients without prescription medication insurance coverage into the 
institutionally sponsored medication program (sponsored by the pharmaceutical 
industry). Medicare Plan D, the federally sponsored Medicare prescription drug 
coverage plan began January 1, 2006. Medicare Plan D has substantially changed 
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prescription drug coverage options for Medicare patients, and may significantly affect 
prescription drug non-adherence rates for this population. Pharmaceutical industry 
sponsored programs for medically indigent patient (such at UT Health Center patients) 
have been affected by Plan D. In fact, many low-income Medicare beneficiaries who 
were enrolled in the drug benefit program receive no help from patient assistance 
programs, as many pharmaceutical companies have ended their pharmacy assistance 
programs. 
 The study examined prescription drug nonadherence for Medicare patients at 
University of Texas Health Center at Tyler (UTHCT) Internal Medicine Clinic. This study 
evaluates drug non-adherence in the studied population prior to and following the 
implementation of Medicare Plan D. 
 
Significance of the Problem 
It is not surprising that people with low incomes, older adults and those with 
chronic health problems face the biggest challenge with medication compliance. A 
patient’s decision to not fill prescriptions, take smaller doses than prescribed or skip 
doses altogether can lead to serious health complications, more hospitalizations, 
increased nursing home admissions and more acute visits to the emergency 
department. With more and more doctor’s visits resulting in prescriptions being written, 
medication noncompliance can be a probable occurrence in the segment of the 
population with no insurance coverage, those with low incomes and the elderly. 
 The consequences in drug noncompliance in the elderly population can be very 
serious. Salzman (1995) estimates noncompliance rates in the elderly to range from 
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40% to 75%. He found three forms of medication noncompliance in the older population: 
forgetting to take the medications, over or under use of medication including medication 
abuse, and modification of the dosages or scheduling of medications. He indicated the 
most common noncompliant behavior in the elderly was under use of the prescribed 
medication; however, discontinuing the medication can occur in 40% or more of 
situations. 
One year before the implementation of Medicare Plan D, Soumerai, Pierre-
Jacques, Zhang, Ross-Degnan, Adams, Gurwitz, Addler, & Safran, et.al. (2006) found 
13% of elderly beneficiaries reported cost-related medication non-adherence. Those in 
fair to poor health with comorbidities and without coverage were most at risk. 
Sambamoorthi, Shea & Crystal (2003) found that in 1997, almost 8% of the older 
population or more than 2.3 million people spent more than 10% of their income on 
prescription medications. Despite pharmacy coverage, out-of-pocket cost burden fell 
most heavily on those with chronic health conditions and women.  
Some describe Medicare Plan D as a real benefit for seniors, while others 
describe the program as a giveaway. There has been much debate on the role of the 
federal government in this program, particularly as it relates to applying pricing pressure 
on pharmaceutical companies. The new Medicare law has been labeled as a perfect 
plan for completely bankrupting the national health care budget by shifting those from 
Medicaid, which required companies to discount drugs by a minimum of 15%, to a new 
plan, Medicare Plan D, which prohibits discounts (Big Pharma Cashing In, 2006). 
 Saving (2005) states 
That in terms of the financial obligation caused by Medicare Plan D and owed to 
the current generation, the difference between income from premiums and  
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expected expenses and expenditures is $6.2 trillion. He goes on to say that 
$10.3 trillion will be added to this debt if premiums remained unchanged and 
projected benefits are paid. He calculates the unfunded liability of Medicare Plan 
D as $16.6 trillion. (p. 4) 
 
In testimony before the Committee on the Budget in the United States Senate, 
Butler (2007) representing the Heritage Foundation, stated, “Cost projections for the 
Medicare drug entitlement program were $822 billion through 2017. He further states 
that costs will be $60 billion per year by 2012 and $119 billion per year by 2017” (p. 5). 
According to his testimony, unfunded obligations on future generations have increased 
by a present value of $7.9 trillion, a figure which is larger than the entire publicly held 
debt in 2000.  
 Prescription coverage for the dual eligibles, those who were covered by both 
Medicaid and Medicare, shifted from Medicaid to the new Medicare prescription drug 
plan in 2006. States are now required to pay the federal government 90% of the cost of 
the prescription drug benefits of these dual eligibles. This is referred to as clawback 
payments. Even though states had previously paid all of the cost of these benefits for 
Medicaid recipients, it is unknown if this will truly result in a savings to the states. Many 
times states may have been able to negotiate for rebates or discounts, so this 
percentage may not be a true reflection of spending. Additionally, even though over time 
the 90% will decrease to 75% of prescription drug costs for dual eligibles, there is an 
inflation factor built into the clawback payment structure. It remains to be seen how the 
individual states will fare under this system. Initially, though, it does appear that the 
states may not receive as much Medicaid relief as they had expected would accompany 
a Medicare prescription drug benefit. With many states situations being different, it is 
difficult to predict the full impact on state budgets. 
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 Medicare Plan D is projected to lower costs of medications for most elderly 
patients. However, seven million of these Medicare beneficiaries are projected to fall 
into the doughnut hole. This stay in the hole can last as long as seven months. This, of 
course, is based on annual drug costs. These patients are significantly more likely to try 
to cut their costs, an activity which can surely lead to non-adherence. Cost-cutting 
strategies on the part of the patient can also jeopardize other necessities, such as 
housing and food (Tseng, Brook, Keeler, Steers, & Mangione, 2004). 
 Despite some relief for some patients in prescription costs with Medicare Plan D, 
3.8 million Plan D beneficiaries are expected to have annual out-of-pocket costs 
between $750 and $3,600, and another 3.1 million may have more than $3,600 in out-
of-pocket costs for prescriptions. Of these 6.9 million, 28% have incomes less than 
150% of the poverty level. Although these patients would probably qualify for low-
income subsidies, it is estimated that almost 40% of beneficiaries eligible for subsidies 
may not enroll (Estimates of beneficiaries’ out-of-pocket, 2004). Without these 
subsidies, patients with low incomes and high medication costs could spend 25% of 
their income on prescription drugs (Stuart, Briesacher, Shea, Cooper, Baysac, 
Limcangca, M., 2005). Or, in many cases, patients may decide to not fill their 
prescriptions, skip doses or take smaller doses of their medications in order to cut their 





REVIEW OF THE LITERATURE 
Medicare Plan D: Impact on Medication Compliance in the Elderly 
 Beginning in 2006, the Medicare Prescription Drug, Improvement, and 
Modernization Act began offering prescription drug benefits to approximately 43 million 
Medicare beneficiaries nationwide. The Medicare Modernization Act (MMA) represents 
the most substantial expansion of Medicare since the program began 40 years ago. It 
was projected to cost the government $720 billion in the first 10 years (Lee, 2005). This 
program will operate through private insurance plans (Safran et al., 2005).  
 Historically, Medicare has not provided coverage for outpatient prescription 
drugs. Because of the important role prescription drugs play in health care, particularly 
in older adults, and the rising costs associated with medications, Plan D was advocated 
as a strategy to lower cost for older adults and to improve drug-taking behavior. 
 
The Plan 
The MMA was passed by the legislature in 2003. A part of this major legislation is 
Medicare Plan D, which is the outpatient prescription drug benefit which became 
effective in January, 2006. 
Prior to the passage of Medicare Plan D, there was overwhelming public support 
of the older population for the addition of a prescription drug benefit to Medicare. 
However, the Henry J. Kaiser Family Foundation (Kaiser Foundation, 2005, March/April) 
found that the older adults’ views of the new prescription drug benefit were mixed. 
Between February 2004 and December 2004, approximately 50% of older adults 
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expressed an unfavorable impression of the new law, compared with about 30% who 
said they have are in favor of the new Plan D. By April 2005, more seniors said they had 
an unfavorable impression (34%) than a favorable impression (21%). However, nearly 
half of these seniors had a neutral impression or said they did not know what to expect 
and had made little to no investigation as to this new plan’s impact on their own drug 
purchases. 
 Prior to the inception of Medicare Plan D, the Kaiser Foundation (2005, August) 
found there were gaps in older adults’ understanding of the prescription drug benefit 
and its impact on their particular situations. In fact, about 68% admitted they did not 
have a good understanding of Plan D, and, therefore, did not know how it would affect 
them personally. By April 2005, few older adults said they were planning to enroll in a 
new drug plan: less than one in ten (9%) said they would enroll, while nearly four in ten 
(37%) say they would not. The majority of seniors said they either had not heard 
enough to decide (47%) or did not know (7%) whether they would enroll (Kaiser 
Foundation, 2006, July 27). But, as it turned out, around 30 million had prescription drug 
coverage through Medicare in 2006, the first year of the new program (Medicare Part D: 
What’s new, 2007). About 12 million were expected to maintain their insurance 
coverage through their employer (Wolf, 2005). In mid-2006, more than eight in 10 
seniors who were enrolled in the prescription drug plan were satisfied with their plan 
even though almost 20% indicated they encountered a major problem using the 
program (Kaiser Foundation, 2006, December 13). The Kaiser Foundation also found 
that nearly 90% of those reporting minor problems indicated satisfactory solutions to 
those problems. 
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In the new Medicare Plan D drug benefit, beneficiaries with high medication 
expenditures also face a period without drug coverage when their total drug costs 
exceed annual caps but are not high enough to qualify for catastrophic coverage. This, 
of course, can be problematic for this segment of the older population.  
 The MMA, which was strongly supported by drug manufacturers, is a voluntary 
program that is administered by private companies. This act has two specific features 
that have evoked considerable criticism. The first concern is that there is a very 
formidable gap in coverage. During 2006, participants in the plan paid the first $250, 
and then they had a co-pay of 25% for the next $2,250 of prescription expenditures per 
year. Then there is no coverage until the senior has spent $5,100. This gap, which has 
been referred to the doughnut hole, was inserted in an attempt to keep the costs of the 
drug coverage program less than $400 billion over a 10-year period (Altman, 2004). 
Once the beneficiary had spent a total of $3,600 out of pocket expenses, which included 
the deductible, the drug coverage would then resume. The beneficiary paid 5% of 
covered drug costs or a co-payment up to five dollars. There was no yearly limit. 
Studies have shown that when out-of-pocket expenses for drugs increase because of 
increasing co-pays or loss of drug benefits, patients respond by skipping or 
discontinuing medications (Kaiser Foundation, 2002). 
In 2007, the coverage gap, or doughnut hole has changed. The limit for the 
beneficiary’s out-of-pocket expense is $2,400. Once that limit has been reached, the 
beneficiary must then pay $3,850 from their own funds before the plan will resume 
paying for prescriptions. About one-third of the plans will offer coverage in the doughnut 
hole, with premiums averaging $40 to $50 per month. Other changes for 2007 include a 
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change in the yearly deductible from $250 to $265 (Medicare Prescription Plans: What’s 
new, 2006).  
Welch (2005) expounded on some of the key features of the Medicare Plan D 
prescription coverage program. The coverage is not based on income. Anyone on 
Medicare can enroll, but the poor will be eligible for subsidies to cover out-of-pocket 
expenses, including premiums, co-payments and deductibles. Welch also stated that an 
estimated 14 million older adults, or approximately 30% of the Medicare population, 
would be eligible for additional aid in 2006. 
 Welch continued to detail how lower income older adults might qualify for 
increased assistance with their individual drug costs. For those who qualified, the 
federal government planned to pay 85% to 100% of their costs. The lower 
socioeconomic group of older adults would have more of their costs covered.  
 To qualify for this additional assistance, older adults must have incomes of less 
than $14,355 for individuals and $19,245 for couples, respectively, and limited assets. 
The assets that would be assessed included savings, investments and real estate other 
than the home where they live, which may not be worth more than $11,500 for 
individuals and $23,000 for couples. 
 A study by Pear (2005) showed the premiums for free-standing drug coverage  
would start as low as $l.87 per month, under a plan offered by Humana in a seven-state 
region which included Iowa, Minnesota, Montana, Nebraska, North Dakota, South 
Dakota and Wyoming. The monthly premiums ranged from $13.58 to $99.90 with three 
drug plans offered in the same region by a consortium of Blue Cross and Blue Shield 
Association companies. A plan through the American Association of Retired Persons 
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(AARP), the grassroots lobby for older Americans, is available nationally, but charges 
vary by state. The premium is generally $23 to $26 per month.  
The average premium for Plan D coverage in 2007 is around $29 per month. 
There are some plans as low as $5 to $20, but the lowest premiums in most areas will 
be about $20 (Medicare Prescription Drug Plans: What’s new, 2006). 
 The number of national drug plans offering coverage in every state has risen to 
17 in the second year of Medicare Plan D. The average number of drugs covered by 
insurers increased by 13% in 2007 to 4,390 drugs with coverage (Pear, 2007). 
 Those who are eligible for both Medicare and Medicaid are automatically 
deemed eligible for low-income subsidies. Other low-income beneficiaries of Medicare 
will have to meet both an income and asset test to be eligible for assistance. Asset tests 
are generally used for various low-income programs to focus benefits toward those truly 
low-income individuals and to exclude those with limited incomes but substantial assets 
available to them. 
Rice & Desmond (2005) estimated that in 2006, when the new Medicare 
prescription drug benefit went into effect, 2.37 million low-income Medicare beneficiaries 
would not qualify for subsidized coverage because they failed the asset test. This meant 
these individuals would face the same doughnut hole as other beneficiaries—which 
means substantial out-of-pocket expenses.  
This study by Rice & Desmond (2005) also looked at the types of beneficiaries 
and the types of assets which were involved. They found that the asset test fell most 
heavily on those who were widowed. Even though only 29% of Medicare beneficiaries 
are widowed, almost half of those were women. Additionally, widows who tend to live 
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alone are generally older and have more chronic illnesses necessitating prescription 
medications, also were found to have less family support. 
 As expected, they also found that most individuals who failed the asset test 
tended to have rather modest assets, which included small bank accounts and relatively 
no stocks, mutual funds or bonds. They also had little in the way of Individual 
Retirement Accounts (IRA) and 401(k)s, real estate (other than their home) and virtually 
no business equity. 
 
Statement of the Problem 
Drug Expenditures 
The four decades since Medicare was enacted have seen a remarkable increase 
in the expenditures for prescription medications. Medicare beneficiaries make up about 
12% of the population and account for about one-third of total United States (U.S.) drug 
expenditures (Steinberg, E.P., Gutierrez, B., Momani, A, et al., 2000). On average, 
people ages 75 to 79 spend 25% more on drugs than those 65 to 69. Nearly 20% of 
people on Medicare are projected to spend at least $5,000 per person in drug costs 
during 2006 (Novelli, 2005). This study did not include the increases in prescription 
medicine expenditures in the oldest old, or those individuals who were over 80 years 
old. 
 In reviewing out-of-pocket expenses and unmet health needs related to obtaining 
prescription drugs for the U.S. civilian population in 2002, it was found that only 16% of 
all families did not have an out-of-pocket expense for prescription drugs (Crimmel & 
Stagnitti, 2005). Families without an elderly member were more than 3 times as likely 
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not to have an out-of-pocket expense (19.2%) than families with an elderly member 
(5.4%). Slightly more than one-fifth of all families included at least one elderly person. 
There are multiple factors that have caused the marked increase in expenditures 
for prescription drugs by the Medicare population over the last several decades. With 
the aging of our population as well as the increasing numbers of Baby-boomers 
reaching retirement age, the number of seniors with chronic conditions requiring 
prescription drugs is increasing and will continue to increase. Medical research has led 
to the development and availability of an increased number of new and effective drugs 
for the treatment of these chronic various conditions (Kaiser Foundation, 2004). In fact, 
with the first of 70 million boomers beginning to turn 60 this year, the problems of health 
care and prescription drug coverage are magnified (Doctors for boomers, 2005). The 
average number of medications per senior is increasing. From 1997 to 2001, there was 
a 23% increase in the number of prescriptions per senior (Kaiser Foundation, 2004).  
 Another major cause of the increase in drug costs in the U.S. is that the prices of 
brand name drugs are much higher than in the rest of the world (Kaiser Foundation, 
2003). Most other industrialized countries limit drug prices by a variety of methods, such 
a formulary pricing, reference pricing or price controls. These techniques have been 
highly effective: prices of brand name drugs in other industrialized nations are 34%-59% 
lower than in the U.S.  
 Moeller, Miller & Banthin (2004) reported that the cost of prescription drugs had 
increased 26% greater than the rate of inflation between 1997 and 2001. Families USA 
(2004) reported that the average wholesale price of 30 brand-name drugs most 
prescribed for seniors had increased by 22% from 2001 to 2004. 
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 Within the three months after passage of the Medicare Prescription Bill Act in 
December 2003, brand-name drugs increased in cost by 3.4%. This was compared to 
an inflation rate of 1.2% (AARP Public Policy Institute, 2004). The pharmaceutical 
industry espouses that these price increases are related to increased expenditures for 
research and development of pharmaceuticals (Families USA, 2004).  
 Of course, as the number and cost of prescription medications has accelerated, 
the cost of drugs per individual has increased. In 2003, the average expenditure per 
Medicare beneficiary that was paid by a senior or by a third party was $2,322 per year 
(Oliver, Lee & Lipton, 2004). The Congressional Budget Office estimated that the 
average cost of drugs per beneficiary in 2006, which was the first year of Medicare’s 
Plan D prescription benefit program, would be $3,155 (Iglehart, 2004).  
 Drug costs for the older adults with multiple chronic health conditions are much 
greater than the averages for the total senior population (Steinberg et al., 2000). In 
1995, 5% of seniors had drug costs greater than $4,000. This figure increased to 16% 
according to the Kaiser Foundation (2003). Fox (2003) found that in 1998 over 10% of 
seniors had drug expenses more than $6,000. 
 
Drug Compliance 
 With almost two-thirds of Americans using medications, compliance has become 
a troublesome issue. Of those currently using medications, 49% use prescriptions 
drugs, while almost 30% use non-prescription medications. Twenty-two percent of 
Americans take less than prescribed of the medication, with 12% not filling their 
prescription at all. Another 12% of Americans do not take their medications even after 
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they have purchased them. Ten percent of all hospital admissions and 23% of all 
nursing home admissions are the result of patients not taking their medications 
correctly. The average length of stay in the hospital due to medication noncompliance is 
4.2 days. Two-thirds of all Americans fail to take any or all of their prescription 
medications (Statistics you need to know, (n.d.)  
 Goldman, Joyce, Escarce, Pace, Soloman, & Laouri, et al. (2004) found that 
rapid changes in drug benefits have shifted a larger burden of pharmacy drug costs 
onto the beneficiaries. Beneficiaries have responded by reducing their use of drugs. 
Their study revealed that the populations most sensitive to price changes were the 
patients taking long-term medications who were not receiving ongoing care for a chronic 
condition with at least two medical visits per year associated with the chronic disease 
care. 
 Patients who are concerned about out-of-pocket medication costs often restrict 
their use of prescription drugs (Steinman, Sands & Covinsky, 2001). Since patients with 
multiple chronic illnesses often take several medications, they are particularly 
susceptible to the higher medication costs. Chronically ill patients who restrict their 
medication use because of cost often restrict essential medications such as 
hypoglycemics, diuretics, bronchodilators, and antipsychotics. This underuse of these 
medications for chronic health conditions has been associated with serious health 
consequences including increased emergency room visits, nursing home admissions, 
acute psychiatric hospitalizations, and a self-reported decline in health status (Martin & 
McMillan, 1996; Soumerai, Ross-Degnan, Avorn, McLaughlin & Choodnovsky, 1991). 
 The Kaiser Foundation (2003) conducted a survey which found that four in ten 
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older adults admitted that they had not taken all the drugs their doctors prescribed for 
them in the past year. There were numerous reasons for their non-compliance: because 
the cost of the drug(s) were too high, because they did not think the drugs were helping 
them; or because they did not think they needed them.  
 Other findings of the survey found that of the 89% of older adults who report 
taking prescription drugs in the past year, nearly half (46%) take five or more, more than 
half (54%) have more than one doctor who prescribes the medicines, and about a third 
(35%) use more than one pharmacy. Among older adults with a minimum of three 
chronic health conditions, nearly three of four (73%) take five or more medications 
regularly and more than half (53%) do not take all their drugs as prescribed (Kaiser 
Foundation, 2003).  
Studies have shown that when out-of-pocket expenses for drugs increase 
because of increasing co-pays or loss of drug benefits, patients respond by skipping or 
discontinuing medications (Kaiser Foundation, 2002).  Tamblyn et al. (2001) studied the 
effect of increasing out-of-pocket drug expenses on compliance with drug therapy and 
its consequences. In Quebec, Canada, prior to 1996, prescriptions were free for the 
older population if they were of lower socioeconomic status and, if not poor, they paid 
two dollars per prescription. In 1996, the law was changed: the co-pay became $25 per 
prescription. Drug use was examined before and after the new law became effective. 
After the new law, 9% of the elderly discontinued essential drugs. The incidence of 
adverse events (defined as first acute hospital admission or death) in those who 
discontinued essential drugs doubled with the statistics showing a rise from 5.8 to 12.6 
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per 10,000 person-months. Further, there was a significant increase in emergency room 
visits by those who discontinued essential drugs. 
The Kaiser Foundation (2003) also found that the average senior’s out-of pocket 
spending for prescription drugs increased from $644 in 2000 to $1,147 in 2004. Of 
course, the seniors who are most vulnerable to the increasing costs of drugs are those 
with multiple chronic conditions who are poor and have no drug coverage. Thirty 
percent of seniors have at least three chronic medical conditions that require 
prescription medications (Moxey, O’Connor, & Novielli, 2003).    
 Seniors who are poor but not on Medicaid may spend 50% of their income on 
health care, prescription drugs, and co-pays (Sourmerai & Ross-Degnan, 1999). As an 
example, middle-aged and older Americans with heart disease who have cut back on 
their prescribed medications because of cost were 50% more likely to suffer heart 
attacks, strokes, or angina than those who did not report cost-related medication 
underuse (NIH News, 2004). Rector and Venus (2004) studied Medicare beneficiaries in 
five states and found 13% did not fill or refill their prescriptions because of cost. 
 
Drug Coverage 
 Approximately 10 million older adults, or about one in four Medicare 
beneficiaries, are without prescription drug coverage (Congressional Budget Office, 
2003). According to a National Council on Aging report, between 3.4 million and 4.4 
million Medicare beneficiaries qualify for the subsidy program under the prescription 
drug benefit program, however, they have not applied for the assistance. This report 
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also found that 2.9 million Medicare beneficiaries who are not enrolled in Medicare Plan 
D do not have any other coverage (National Council on Aging (NCOA), 2007).  
Drug coverage has been shown to make a substantial difference in compliance 
issues for chronic conditions, with 37% of seniors without drug coverage reporting cost-
related non-adherence, compared with 22% of seniors with drug coverage. Low-income 
older adults without the benefit of drug coverage generally took fewer drugs than those 
with drug coverage. Older adults also reported wide differences in the source of their 
drug coverage across states. Nationally 29% of seniors reported having employer-
sponsored drug coverage, but state rates for employer-sponsored drug coverage 
ranged from 24% in Washington to 47% in Michigan.  
 The Congressional Budget Office (2003) also questioned the older adults about 
their prescription purchases from other countries. Overall, one in twenty seniors (5%) 
reported having obtained their prescription drugs from pharmacies in Canada or Mexico. 
Again, these rates varied across the U.S., from a high of 11% in Washington to a low of 
2% in New York. Older adults without the benefit of a drug coverage program were 
more likely to obtain drugs from Canada or Mexico. Nationally 11% of seniors without 
drug coverage reported obtaining drugs from either Canada or Mexico, with state levels 
ranging from 19% in Colorado to 5% in Tennessee (Kaiser Foundation, 2003). 
 A study done by Tseng, Brook, Keeler, Steers, & Mangione (2004) found that 12 
of the top 20 therapeutic classes of prescription medications most affected by 
decreases in use were for chronic health problems such as hypertension, 
hyperlipidemia, and emphysema or asthma. They contend that one of the major 
reasons for non-compliance with medication use was that the majority of Medicare drug 
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benefits in managed care have annual dollar limits or caps and many beneficiaries face 
temporary but potentially significant gaps in coverage after exceeding the caps before 
the end of the year.  
 
The Implications 
Drug Pricing Negotiations 
 Congress has prohibited the federal government from negotiating drug prices 
directly with pharmaceutical manufacturers. This has been a highly controversial 
decision and has added to the complexity of the program because instead of having a 
single, government-negotiated price schedule and formulary, each Medicare-approved 
prescription drug plan will negotiate its own pricing. This means that each will have their 
own preferred drugs, subject, of course, to federal guidelines. This will certainly affect 
the out-of pocket expenses of the beneficiaries because their expenses will directly 
depend on whether their plan’s preferred list includes the drugs that they take. Those 
that they take that are not on the preferred list will pay more. 
 Politics has not eluded the Medicare Plan D. Most Republican Congressmen 
have opposed government price-setting and believe the private sector can do a better 
job. By prohibiting direct price negotiation, Congress also could forestall opposition from 
drug manufacturers that might have sunk the bill. 
 Many Democrats have bitterly opposed the bill that created the Medicare Plan D 
drug benefit. For the most part, they have favored using the government directly to 
administer the new coverage. They continue to argue that the benefit remains 
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complicated and the real reason for using the private sector to administer the benefit is 
to repay the drug manufacturers for their support of the Republican Party. 
 There is the belief that prescription drug costs may cause considerable strain on 
the federal government’s ability to fund the program while meeting all other obligations. 




 There seem to be some serious questions about the asset testing portion of the 
new drug benefit. Americans have always been encouraged to save for their retirement 
years. Those with the least potential for saving for the future will most probably have 
little or no income other than what they receive from Social Security. If these same 
people had been able to save and accumulate modest amounts of assets, they most 
surely would not qualify for the low-income Medicare subsidies, even though the biggest 
majority of them are using prescription drugs every day. Those who did save will not be 
able to qualify for subsidies. Those who did not will have the subsidies, but nothing else 
for retirement except their Social Security. The majority of those caught in this dilemma 
are the most vulnerable of our older population. 
 
Drug Company Programs vs. Medicare Plan D 
 Havrda, Omundsen, Bender & Kirkpatrick (2005) studied the impact of the MMA 
on lower income Medicare beneficiaries without prescription benefits who received 
assistance from pharmaceutical companies for medications. The findings showed that 
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the MMA offered the low-income Medicare population previously with minimal or no 
drug coverage, lower drug costs than those they would have incurred by obtaining 
medications without any assistance. The population they studied received help with 
medications through the pharmaceutical companies’ programs. This help resulted in 
substantial savings in total drug costs. In this group, Havrda et al. (2005) found that the 
Medicare drug discount program resulted in out-of-pocket costs that exceeded those 
associated with pharmaceutical company assistance programs. The Medicare 
prescription benefit offered greater savings to individuals with incomes less than 135% 
of the Federal Poverty Level (FPL) than to any other group. They also found that groups 
with incomes of 135% to 150% of FPL and greater than 150% of FPL had reduced out-
of-pocket expenses with the prescription benefit compared to no assistance at all; 
however, an advantage over the pharmaceutical company assistance programs was not 
evident. Many pharmaceutical companies ended their pharmacy assistance programs 
after the Medicare prescription benefit began. They site concerns that the programs 
could violate anti-kickback laws (Appleby, 2007). 
 
Conclusion 
 The need to provide adequate drug benefits for all older adults is great. As has 
been expected, there is still much confusion and lack of understanding on the part of 
those who are intended to be helped by Medicare Plan D. As with any new program, 
there are and will be problems and hurdles to overcome. With any government program, 
keeping costs down and benefits up is a difficult challenge.  
 There should be some areas in the future where the public and private sectors 
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should be able to collaborate in order to provide effective data and evidence for 
program modification, enhancement and new program development. There will surely 
be independent analyses and research based on the data on drugs, medical outcomes, 
chronic disease progression, costs and other data which can be extrapolated from a 
medication program like Medicare Plan D. It would be hoped that as a result of this 
research this program could then be used to provide better services, more targeted 
assistance, improve medication compliance and lower costs as the program evolve. 
It will be interesting to see how the doughnut hole in coverage will affect older 
adults. Some say this gap in coverage will be of marginal benefit to older adults with 
multiple medical conditions. Could ways be devised to eliminate the gap without 
increasing expenditures? If so, who would pay? What effect will lack of negotiations by 
the federal government for drug pricing have on the overall program? Will drug benefits 
effectively reduce cost-related under use of drugs and improve clinical outcomes?  
 These and many other questions beg to be answered in the second year of this 
new drug benefit program. Research on all aspects of this program should be ongoing 
and hopefully will provide at least some direction, if not answers. 










 Criterion for Inclusion 
 Any English speaking University of Texas Health Center (UTHCT) Internal 
Medicine Clinic (IMC) patient who is enrolled in the Medicare program and age 65 years 
or older was invited to participate in this study by completing a survey. Participation in 
the study was completely voluntary. Completion of the survey took approximately 10 
minutes and involved no foreseeable risks. Consent was considered to be obtained by 
the completion of the survey. All respondents’ information was completely confidential 
as there were no identifiers of any kind on the survey.  
 
Protection of Human Subjects 
 Prior to participating in this study, participants were given verbal as well as 
written information, and permission was granted by the University of North Texas 
Institutional Review Board (See Appendix C). Completion of the survey indicated 
consent. Participants were assured verbally and in writing of the confidential nature of 
the information collected. Surveys contained no identifying information of any kind. 
Participation was completely voluntary. All data collected were kept in a locked file 
cabinet on the 5th floor of the University of Texas Health Center at Tyler.  
 
Sample 
 The sample collected was a census sample. The numbers of completed surveys 
were expected to be 450-500; however, 789 completed surveys were collected. The 
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response rate was approximately 22%. These surveys were collected at two different 
times. The first survey was done in October and November, 2005, prior to the 
implementation of Medicare Plan D. The second survey was done in October and 
November, 2006, after Medicare Plan D became effective on January 1, 2006. Only 
patients of UTHCT IMC who are 65 years or older, Medicare beneficiaries and English 
speaking were offered the opportunity of participating in the survey. 
 
Survey 
 The survey tool developed for this study was a 36 question survey. Questions 
included demographic information such as age, sex, ethnicity, education, and marital 
status. Other questions queried the financial assets and monthly income of the patient, 
as well as questions related to the type of medication prescription insurance currently 
been utilized and questions directed toward medication compliance issues. Copies of 
this survey are found in Appendix A and Appendix B. The only difference in the surveys 
is question 12. The first survey conducted which was conducted in 2005 reflected the 
use or non-use of Medicaid to help pay for prescriptions, while the second survey, 
completed in 2006, identified those who did or did not utilize the new prescription benefit 
program, Medicare Plan D. 
 
Research Methodology 
 I transferred the data from the completed survey forms to a Microsoft® ACCESS 
2006 database.1 After the data were entered into the database, it was exported to 
                                        
1Microsoft Corporation, www.microsoft.com . 
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SPSS™ statistical software2 for analysis. Investigations were done by looking at 
medication compliance issues prior to and after the implementation of Medicare Plan D. 
Statistics were compiled by using cross tab tables with chi-square reporting. 
Comparison of t-tests were also done. The outcome measure was always the 
compliance variable of - did not fill prescriptions because of expense. The outcome was 
evaluated in terms of the types of insurance coverage the respondent may have had, 
whether or not they had Medicaid and whether they utilized Medicare Plan D. Other 
evaluations were done exploring the effects education, gender and race may have had 
on nonadherence in the studied population.  
                                        




 The first survey done in fall 2005 had 480 respondents, while the second one, 
completed in fall 2006, had 309 respondents. Both groups, however, showed many 
similarities in the general population characteristics. Approximately 65% of the 
respondents were women in both periods, while men were approximately 35% of those 
who responded. The average age of the surveyed population was 73.5 years in the first 
group and almost 75 years in the second group. Most of the respondents in both time 
periods were married, with 27% and 30%, respectively, indicating they were widows. 
Approximately 28% lived alone with over 80% in both surveys indicating they were 
Caucasian. The 2005 survey included 16.5% African Americans, while the 2006 survey 
showed 12.5% African Americans. Approximately 33% of all respondents had a high 
school education or more. Over 85% of all respondents indicated they took prescription 
medication, with 6 medications as the average taken by those surveyed. As shown in 
Table 1 the pre and post groups were quite similar except for decline in the number of 
minorities in the second sample. 
Particular attention was given to drug compliance in the pre and post periods. 
The pre period included those respondents in fall 2006, while the post period was in fall 
2006; about 10 months after Medicare Plan D became effective. Data analyzed for 
compliance included questions related to always filling prescriptions, never skipping 
doses and never taking smaller doses in order to make medications last longer.  
Approximately 70% of respondents in the pre group always filled their prescriptions, 
compared to almost 79% in the post group as depicted in Table 2.  
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Table 1 
General Population Characteristics of Samples in Two Surveys 
  PRE POST 
% 64.8 66.1 Women 
n 469 307 
% 73.48 74.88 
Average Age 
n 478 308 
% 63.3 62.0 
Married 
n 477 308 
% 26.8 29.9 
Widowed 
n 477 308 
% 28.6 27.6 
Lives Alone 
n 477 308 
% 81.6 86.7 
Caucasian 
n 474 30 
% 16.5 12.3  
African American 
n 474 309 
% 33.5 33.6  
High school & more 
n 478 307 
Total in Samples  480 309 
 
   
Table 2 
Prescriptions Not Filled During a 12 Month Period Due to Expense 
  Always Filled 
Did not fill 
1 or more times Total 
Missing 
Data 
%    70.4   29.6 Pre 
n 304 128 
432 48 
%    78.5   21.5 
Post 




The results were very similar for the other two compliance questions. In the pre 
group, 70% said they never skipped doses in order to make the medication last longer. 
In the post group, 78.95% indicated they never skipped their medication (See Table 3) 
Table 3 
Doses Skipped During the Last 12 Months to Make Prescription Last Longer 
  No / Never Yes, Sometimes or Often Total 
Missing 
Data 
% 70.0 30.0 Pre 
n 296 127 
423 57 
% 78.9 21.1 
Post 




In terms of taking smaller doses in order to make their medication last longer, 
71% of those in the pre group indicated they had never done so while 79.6% in the post 
group indicated they had never taken smaller doses. (See Table 4)  
Table 4 
Smaller Doses Taken During the Last 12 Months to Make Prescription Last Longer 
  No / Never Yes, Sometimes or Often Total 
Missing 
Data 
% 70.7 29.3 Pre 
n 302 125 
427 53 
% 85.4 14.6 
Post 




Overall, about 70% were compliant in these three areas before Medicare Plan D, 
and approximately 79% were compliant after Medicare Plan D. These increases might 
possibly be related to the acquisition of Plan D by some who may have had no other 
coverage previously.  
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From Time 1 to Time 2 there were some interesting shifts in coverage. The most 
significant was in benefits for prescriptions. When asked whether they had insurance or 
benefits to help pay for prescriptions, 52% of the respondents in the pre period said they 
had some type of benefits to help them. However, that figure increased to almost 80% 
in the post period. This increase might be due to an increase in those respondents who 
now had coverage under Plan D. Those with coverage through their job or employer 
remained fairly stable between the two periods. However, those with insurance they 
bought for themselves (private insurance) increased from 19.6% in the pre period to 
30.7% in the post period. This increase in those who said they had private insurance 
after Medicare Plan D became effective might be because those who now had Plan D 
coverage may have considered that to be a form of private insurance. Some people 
may have had both private insurance and Medicare Plan D. (See Table 5)  
Table 5 
Benefits and Types of Coverage 
 Pre Post 
 % n Missing Data % n 
Missing 
Data 
Have Benefits for Prescriptions 51.7 441 39 79.9 288 21 
Company Drug Insurance 28.4 447 33 25.9 297 12 
Private Drug Insurance 19.6 443 37 30.7 290 19 
VA Drug Insurance 11.9 438 42 14.9 287 22 
Pharmacy Discount Card 20.3 444 36 10.7 444 19 
UT Pharmacy Assistance 
Program 24.7 438 42 8.0 288 21 
Another Pharmacy Program 6.2 433 47 15.6 275 34 
Part D  (n/a)  51.5   
Medicaid 11.9 441  (n/a)  
Note: n/a = not applicable. 
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Those respondents indicating they had either a pharmacy discount card or utilized the 
University of Texas Pharmacy Assistance Program (UTPAP) sharply declined in the 
post period. This would be an expected finding, as many Pharmacy Assistance 
Programs (PAPs) were not available to help Medicare beneficiaries pay for medications 
after Plan D became effective. However, interestingly, when respondents were asked 
about utilizing another pharmacy program, 15.6% of those in post group responded that 
they did utilize such a program, while only 6.2% indicated such usage in the pre group. 
The analysis of those with either an outside pharmacy assistance program or Medicare 
Plan D showed 17.4% of respondents with both as shown in Table 5. This might be 
explained by the thought that many respondents may see Medicare Plan D as another 
pharmacy program that they now used to help with their prescriptions.  
 Over 50% of the population indicated having Plan D coverage, while previously 
only a small percentage indicated they had Medicaid coverage. It is possible to say 
there was a big boost with Plan D and that might explain the increase in benefits in 
prescription coverage. However, although it is true that the categories of private 
insurance and other PAPs did show increases, these increases are not of significant 
magnitude to explain this boost in coverage.  
 We have now returned to the central question: Did Medicare Plan D enhance 
compliance? Table 6 shows a comparison between Year 1 (pre Plan D) and Year 2 
(Plan D) across compliance questions. Year 2 is further considered in terms of those 
who did and did not have Plan D coverage. Compliance increased substantially in Time 
2 compared with Time 1. However, those increases in compliance were greater in those 
who did not have Plan D. Although overall compliance was increased between the two 
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time periods, the major concern remains as to whether this increase can be attributed to 
coverage. Increased compliance is not explained by having Plan D coverage.  
 At Time 2, after the changes to Medicare coverage, having Medicare Plan D was 
cross tabulated by failure to fill a prescription due to cost and the two variables were 
related, (X 2 = 14.4, p =.013). For those who indicated having Plan D coverage, 71.5% 
indicated never having failed to fill a prescription, while for those without Plan D 
coverage, 86.5% indicated never failing to fill a prescription. Thus, those patients 
covered by Plan D were less likely to be fully compliant in filling prescriptions than those 
without Plan D as Table 6 reflects. 
          Of those with Medicare Plan D, 73.6% indicated that they never skipped doses of 
a medicine in order to make the prescription last longer. Among those without Plan D 
coverage, 85.6% indicated they never skipped their medicines in order to make them 
last longer as shown in Table 6. These variables were found to be significantly related 
to each other (X 2 = 6.0, p =.049). 
 The comparison of those who did or did not have Medicare Plan D in terms of 
taking smaller doses of medicines in order to make them last longer found the two 
variables to be unrelated (X 2  = 4.316, p = .116). Plan D coverage did not significantly 
predict the taking of smaller doses. (See Table 6) 
 Thus, overall, Plan D coverage significantly predicts greater noncompliance in 
sometimes failing to fill prescriptions or in skipping doses to make them last longer. 
Obviously, having Medicare Plan D could not explain the increased compliance on two 




Comparison between Year 1 (Pre Plan D) and Year 2 (Plan D) across Compliance 
Questions                     
  Year 2 (Post) Year 2 (Post) 
  
Year 1 (Pre)
Part D Not Total 
% 70.4 71.5 86.5 78.6 Always Filled 
n 304 140 126 266 
% 70.0 73.6 85.6 79.1 Never Skipped  
Doses n 296 148 125 273 
% 70.7 82.7 88.9 85.4 Never Took 
Smaller Doses n 302 150 126 276 
                           
 
Thus, overall, Plan D coverage significantly predicts greater noncompliance in 
sometimes failing to fill prescriptions or in skipping doses to make them last longer. 
Obviously, having Medicare Plan D could not explain the increased compliance on two 
of these measures. 
Next, the compliance questions were evaluated in terms of those who indicated 
they had some type of assistance to help pay for prescriptions other than Plan D. 
Survey results found that 81.6% of those in the pre period who indicated they had some 
type of benefit or insurance to help with medications always filled their prescriptions. A 
similar number of 81.5% was reported in the post period. However, 58.2% of those in 
the pre period who indicated they did not have any benefit or insurance to help with their 
medication needs reported always filling their prescriptions compared to 72.2% in the 
post period. (See Table 7) Therefore, although an increase in compliance was found 




Those Who Indicated They Had Benefits or Insurance to Help Pay for Prescriptions in 
Terms of Filling or Not Filling Their Prescriptions 
 Always Filled Benefit   
 Pre Post 
% 81.6 81.5 
Yes 
n 178 / 218 181 / 222 
% 58.2 72.2 
No 
n 116 / 199 39 / 54 
 
As displayed in Table 8, in terms of those who did or did not have benefits for 
prescriptions, 73.3% of those in the pre period indicated they never skipped doses 
because of expense. This is similar to 79.5% who had benefits and did not skip in the 
post period. However, 79.2% of those in post period who said they had no benefits or 
insurance for prescriptions indicated they never skipped doses compared to 57.5% in 
the pre period.  
Table 8 
Those Who Indicated They Had Benefits or Insurance to Help Pay for Prescriptions in 
Terms of Those Who Never Skipped Doses 
 Never Skipped Doses Benefit   
 Pre Post 
% 73.3 79.5 
Yes 
n 175 / 210 175 / 220 
% 57.5 79.2 
No 
n 114 / 198 42 / 53 
 
 
In terms of those who responded that they never took smaller doses in order to 
make the medication last longer, 79.8% in the pre period indicated they had benefits 
and were compliant compared to 85.6% in the post period. Of those who said they had 
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no benefits or insurance for medications, 62.8% in the pre period indicated always 
taking a full dose, however, this figure increased to 83.3% in the post period as 
exhibited in Table 9.  
Table 9 
Those Who Indicated They Had Benefits or Insurance to Help Pay for Prescriptions In 
Terms of Taking Smaller Doses to make the Medication Last Longer 
 Never Took Smaller Doses Benefit   
 Pre Post 
% 79.8 85.6 
Yes 
n 170 / 213 191 / 223 
% 62.8 83.3 
No 
n 125 / 199 45 / 54 
 
 
Across the compliance questions in terms of having or not having benefits to help 
pay for prescriptions those without benefits showed positive change in population 
compliance in the post period. There were no significant changes over time in 
compliance in patients with drug coverage. 
 
Effects 
An item evaluating those who never spent less on food or basics in order to buy 
medications can be taken to represent a possible outcome of drug coverage. On this 
item, 70.4% of those in the pre period never spent less to buy their prescriptions, while 
77.5% in the post period said they never spent less on basics in order to purchase 
medicines. (See Table 10) This may be hypothesized to the acquisition of a Plan D 





Those Who Indicated They Had Spent Less on Food or Basics In Order to Buy 
Prescriptions 
Spent Less  Pre Post 
% 11.2 6.9 
Yes, often 
n 47 / 419 20 / 289 
% 18.4 15.6 
Yes, Sometimes 
n 77 / 419 45 / 289 
% 70.4 77.5 
No, Never 
n 295 / 419 224 / 289 
 
The food item, those who never, sometimes or often spent less on food to buy 
medications, was cross tabulated in the post period with Medicare Plan D coverage. 
These variables were found to be strongly related (X 2 = 23.41, p < .001). Of those 
respondents with Plan D, 66.4% never spent less on basic needs in order to buy their 
prescriptions, while 24.2% sometimes did so and 9.4% often did so. In the group who 
did not have Plan D coverage, 90.6% never spent less on food and other basic needs in 
order to buy their prescriptions, while 5.5% sometimes did so and 3.9% often did so. 
(See Table 11) 
Table 11 
Percentages of Those who Never, Sometimes, or Often Spent Less on Food to Buy 
Medication Related to Their Participation in Medicare Plan D 
Medicare Plan D Yes, Often Yes, Sometimes No 
Yes 9.4 24.2 66.4 
No 3.9 5.5 90.6 
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In summary, those with Medicare Plan D were more likely than those without 
Plan D to sacrifice food, in order to fill prescriptions. This could reflect the greater 
economic need of those who have Plan D. Also, many of those who do not have Plan D 
coverage may have had coverage by an employer or job which might be better 
coverage than Plan D. Nevertheless, having Plan D coverage significantly predicted 
sometimes spending less on other necessities in order to afford prescribed medications, 
undermining any expectation that Plan D helped in this regard. 
Table 12 shows a comparison of the amount spent per month on all prescription 
pills in both the pre and post periods. There was an increase in the post period in the 
numbers of expenditures in the $0 to $50 range, but a decrease in expenditures in the 
$51 and over category. The increase in those prescriptions in the lower cost category 
may reflect an increased compliance in filling prescriptions after the acquisition of a Plan 
D policy.  
Table 12 
A Comparison of the Amount Spent per Month on all Prescription Pills in the Pre and 
Post Periods 







Pre 35.7 64.3 401 260 









 The Medicare Plan D prescription drug benefit, introduced in January 2006, 
aimed to relieve the burden of out-of-pocket drug costs for Americans over age 65. 
Results have varied. The hope that Plan D would provide financial relief for many 
seniors may have been a false assumption.  
 The focus of this research has been on the compliance side of medication-taking 
in Medicare beneficiaries before and after the implementation of Medicare Plan D. 
Medication compliance in terms of always filling prescriptions, never taking smaller 
doses and skipping doses in order to make the medication last longer was evaluated. 
We hoped to find out whether having Medicare Plan D improved compliance in seniors. 
 In addition, several influencing factors were evaluated in terms of their possible 
effects on compliance issues in the studied population. The effects of employer 
insurance, private insurance, VA coverage, and several pharmacy assistance programs 
were explored. When asked if they had benefits for prescriptions, those in the period 
after Medicare Plan D was implemented were more likely to indicate they had some 
type of coverage. This could, however, have been related to the acquisition of a Plan D 
policy.  
 No significant changes were found in the compliance issues in those with 
insurance through their employer or job. In today’s changing economic times, this might 
need to be revisited, as more and more companies are modifying or discontinuing their 
health insurance coverage of retirees.  
Those indicating they had private insurance increased in the post period. This 
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might mean that some of the respondents felt acquiring a Plan D policy was a type of 
private insurance, particularly those Medicare beneficiaries who had to purchase a 
policy of their own.  
 Pharmacy assistance programs, including the one at University of Texas Health 
Center, were found to be declining after the introduction of Plan D. One exception was 
an increase in using an outside pharmacy assistance program (PAP). The increase in 
this utilization in the post period might be attributed to the fact that they may have 
looked at the PAP as another a benefit or insurance form to help with prescriptions.  
 In attempting to answer the question as to whether medication compliance 
improved or not after Plan D was implemented, surprising results were found. 
Medication compliance was increased in those respondents who did not have Medicare 
Plan D. Although increased compliance is not explained by having Plan D coverage, 
those without Plan D coverage may have had better coverage through an employer or 
the VA or felt that a purchase of a policy was unwarranted as their medication usage 
was minimal. At the time of this research, the four dollar plans offered by some chain 
stores were just becoming available. Quite possibly, depending on the individual 
situation, the Medicare beneficiary may have been able to avoid a monthly policy fee 
and just pay cash for medications. This would, of course, depend on the medications 
the patient used and whether they were available at the four dollar co-payment. With the 
wide variety of generics available, and the cooperation of those who prescribe, to 
ensure they write prescriptions that will be covered under such plans, it is possible for 
this scheme to be of benefit to some.  
I also suggest that in terms of having Plan D coverage, patients with Plan D were 
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more noncompliant in filling their prescriptions or skipping doses because of expense. 
 In terms of evaluating those with or without benefits to help with prescription cost, 
those who said they did not have benefits or insurance exhibited more compliant 
behaviors in the post period. This, again, could be because of the particular health 
situation of the individual, the number of medications they were taking, or their particular 
financial situation.  
 Plan D coverage was found to be a significant predictor of spending less on food 
or basics in order to buy medications. But, it is possible that those who enrolled in Plan 
D had a greater need than some who did not enroll.  
 Although there were some differences in the amount spent per month on 
medications in the pre and post period, these differences were not significant. 
 The research in this dissertation suggests that although overall compliance may 
have increased in those areas, these increases cannot be attributed to the acquisition of 
a Medicare Plan D policy. It is not clear to this researcher the reasons for increased 
compliance. This is an area where more research with more focused data collection 
might be of benefit.  
 
Limitations 
 The data from this study was collected in two different time periods and in two 
different patient populations. Although the patient pool is very similar for each time 
period and is representative of the patient population at University of Texas Health 
Center at Tyler, changes cannot be attributed directly to changes in persons or changes 
in the population. No multivariate analyses were performed so there was no control for 
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other factors, such as age, gender, living situations and others. Because this is an 
exploratory research study, attribution of effects is tentative. 
The 2003 drug bill was a huge, and, many say, unaffordable new entitlement. 
Medicare faces many challenges; but two major ones loom large in the future. First, an 
aging population with multiple medical problems requiring health care options is 
particularly problematic in a population with a declining number of workers to finance 
health care expenditures. Second, keeping Medicare and Social Security solvent is an 
even bigger problem.  
Baby-boomers and seniors continue to hope for a health care plan that is 
workable, uncomplicated, and affordable and that will maximize their health care 
options. I am not sure Medicare Plan D is that plan. It was intended to be assistance to 
seniors in a time of skyrocketing medication costs, but it may prove to have been an ill-
advised program. If the costs of the program do not lead to major benefits for Medicare 
population, policy makers and politicians will need to redesign the program for the sake 
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